Eculizumab, a monoclonal antibody against the C5 complement protein, is currently used in clinical renal injury settings, mainly for atypical hemolytic uremic syndrome (a-HUS), PNH and in C3 glomerulopathy [25–29]. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.